Long-Acting Insulin (Insulin, Long Acting)

Subscribe to Selected New Research on Long-Acting Insulin

177 relevant articles (9 outcomes, 25 trials/studies) found for this Drug

Description: Insulin formulation containing substance which delays or retards time period of the absorption of insulin.

Also Known As:

Insulin, Long Acting; Mixtard; Protamine Zinc Insulin; Insulin, Long-Acting; Insulin Novo Monotard; Insulin, Lente; Insulin, Lente, Monocomponent; Insulin, Monotard; Insulin, Protamine Zinc; Insulin, Protamine Zinc, Beef-Pork; Insulin, Semilente; Protophan; Ultralente Insulin; Insulin, Ultralente; Lente Insulin; Long Acting Insulin; Monotard Insulin; Monotard, Insulin Novo; Novo Monotard, Insulin; Semilente Insulin; Zinc Insulin, Protamine

Relationship Network

Drug Context: Research Results

Experts

1.	Murad, M Hassan: 1 article (03/2008)
2.	Bolli, Geremia B: 1 article (03/2008)
3.	Cioli, Patrizia: 1 article (03/2008)
4.	Ricci, Natalia Busciantella: 1 article (03/2008)
5.	Fanelli, Carmine G: 1 article (03/2008)
6.	Porcellati, Francesca: 1 article (03/2008)
7.	Rossetti, Paolo: 1 article (03/2008)
8.	Candeloro, Paola: 1 article (03/2008)
9.	Smith, Steven A: 1 article (03/2008)
10.	Bitterman, Haim: 1 article (01/2008)

Related Diseases

1.	Hypoglycemia (Reactive Hypoglycemia) 05/01/2008 - "The use of these long-acting insulin analogues appears to be associated with a reduced incidence of hypoglycemia, especially at night. " 07/01/2004 - "The use of this long-acting insulin analogue appears to be associated with a reduced incidence of hypoglycemia, especially at night. " 01/01/2007 - "CONCLUSIONS: Randomized clinical trials suggest that the long-acting insulin analogs are associated with a lower risk for nocturnal hypoglycemia than neutral protamine Hagedorn without sacrificing glycemic control." 04/01/1997 - "To study this, groups of rats were injected with approximately 25 U/kg ultralente insulin daily at 1700 for 8 days to maintain hypoglycemia. " 09/01/1988 - "The present study was designed to investigate the morphology of adrenal chromaffin cells in rats subjected to chronic hypoglycemia induced by long acting insulin, and to assess this morphology in terms of associated changes in catecholamine content and release. " Order ALL the reference details at left...
2.	Diabetes Mellitus 01/01/2001 - "Efficacy of protamine zinc insulin for treatment of diabetes mellitus in cats." 10/01/1969 - "[Comparative efficacy of long-acting insulin preparations in diabetes mellitus]" 03/01/2009 - "BACKGROUND AND OBJECTIVES: The purpose of this study was to review studies reporting on quality of life and treatment satisfaction of patients with diabetes mellitus being treated with long-acting insulin analogues. " 01/01/2006 - "The analysis of nonadherence to national guidelines revealed: 1) failure to assess patient's height, weight, and body mass index (30.1%); 2) poor glycemia control (26%); 3) failure in referring to an endocrinologist in case of noncontrolled glycemia (17.5%); 4) monotherapy with long-acting insulin or started combined oral therapy without monotherapy (10.2%); 5) noncompliance with the recommendations of endocrinologist (8.5%); 6) unsubstantiated changes in diabetes mellitus treatment (4.1%). " 01/01/2005 - "Diabetes mellitus was diagnosed and treatment with long-acting insulin was started. " Order ALL the reference details at left...
3.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/01/1984 - "The aim was to study the effect of dose on subcutaneous absorption of semisynthetic human Lente-type insulin (Monotard HM) in IDDM patients. " 03/01/2008 - "Type 1 diabetes mellitus treatment includes plain substitution and individualization for short-acting plus long-acting insulin according to the physician's assistance, besides regular practice of physical activities and diet orientations. " 01/01/2008 - "Intermediate acting versus long acting insulin for type 1 diabetes mellitus." 06/01/1995 - "Twelve cats with insulin-dependent diabetes mellitus were treated with lente insulin. " 07/01/2007 - "The aim of this study was to evaluate the efficacy of long-acting insulin analogue glargine (G) changing from NPH in basal-bolus therapy for Japanese children and adolescents with type 1 diabetes mellitus (DM1). " Order ALL the reference details at left...
4.	Weight Gain 09/01/2006 - "AIM: The aim of this study was to investigate whether a regimen free of long-acting insulin can provide long-term glycaemic control without causing weight gain. " 03/01/2004 - "AIM: To test the concept that regain of glycaemic control can be achieved without causing weight gain, using a regimen free of long-acting insulin. " 11/01/1984 - "Peripherally administered, long acting insulin stimulates weight gain and food intake. " 01/01/1983 - "Rats were made to overeat and gain weight (about 50 g) by long-acting protamine zinc insulin (PZI) treatment. " 10/01/1979 - "Effect of protamine zinc insulin on feed intake and weight gain in broiler chicks." Order ALL the reference details at left...
5.	Hyperinsulinism (Hyperinsulinemia) 09/01/2006 - "Peripheral hyperinsulinism induced by the use of long-acting insulin may be the key to explain this adverse effect. " 03/01/2004 - "This adverse effect may be related to chronic hyperinsulinism induced by long-acting insulin compounds. " 02/01/1990 - "In vivo experimental hyperinsulinemia was produced in rats by subcutaneous injection of long-acting insulin at low (10 mU.g-1.day-1), medium (up to 25 mU.g-1.day-1), and high (up to 50 mU.g-1.day-1) doses over 1 or 2 wk. Insulin-stimulated lipogenesis was measured to determine the efficacy of the experimentally produced hyperinsulinemia. " 12/01/1993 - "Because the present therapeutic regimens of NPH/Lente insulin given at suppertime cause overnight hyperinsulinemia, excessive fasting hyperglycemia rarely follows nocturnal hypoglycemia, except when excessive glucose is ingested to correct hypoglycemia. " 03/01/1978 - "High-dose insulin treatment (2 U Protamine-zinc-insulin/100 g per day) resulted in normoglycemia, normal weight gain, mild hyperinsulinemia, and return of glucagon levels toward base line. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	glargine (insulin glargine)
3.	insulin detemir (Levemir)
4.	Glucose (Dextrose)
5.	Hypoglycemic Agents (Hypoglycemics)
6.	NPH Insulin
7.	Zinc
8.	insulin LISPRO (Humalog)
9.	Blood Glucose (Blood Sugar)
10.	basal insulin

Related Therapies and Procedures

1.	Subcutaneous Injections
2.	Carbohydrate-Restricted Diet (Low Carbohydrate Diet)
3.	Injections
4.	Intraperitoneal Injections
5.	Oral Administration

Best Treatments:
Research Summary Report
on Hypoglycemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 407 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>